Jonathan Pargament, MD
Ophthalmology · Springboro, OHNPI 1275848160
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $105,690 of the $115,844 with a category attached, or 91.2%. Amgen accounts for 99.5% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2021 at $43,748 and has fallen 62.1% since, to $16,589 in 2025. Among ophthalmology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 162 payments — averaging $715.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$115K
- Biotissue Holdings Inc.$136
- Bausch & Lomb Americas Inc.$123
- Regeneron Healthcare Solutions, Inc.$104
- Alcon$99
- Novartis$37
- plus $108 from 4 others
What the payments were for
- Consulting fees$1,0501%
- Speaking & faculty fees$105,69091%
- Travel & lodging$4,6314%
- Food & beverage$4,4444%
- Education$290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 140 | $115,239 |
| Biotissue Holdings Inc. | 6 | $136 |
| Bausch & Lomb Americas Inc. | 1 | $123 |
| Regeneron Healthcare Solutions, Inc. | 3 | $104 |
| Alcon | 4 | $99 |
| Novartis | 2 | $37 |
| Lombart Brothers, Inc. | 2 | $36 |
| Halozyme Inc | 2 | $35 |
| Kerecis Limited | 1 | $21 |
| Genentech USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$112,710
- INFUSE MULTIFOCAL$123
How this compares
$115,844 in reported general payments places this provider in the 95th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 808 | $7,849 |
| Bacitracin | 29 | $2,443 |
| Doxycycline Hyclate | 74 | $2,212 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 74 | $838 |
| Methylprednisolone | 94 | $577 |
| Cephalexin | 28 | $505 |
| Ondansetron OdtOndansetron | 38 | $258 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 36 | $230 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Springboro
- Peter KaiserCleveland$1.5M
- Gregory EippertMentor$813K
- Robert OsherCincinnati$720K
- Justis EhlersCleveland$639K
- Lawrence SingermanBeachwood$599K
- Darrell WhiteWestlake$587K
- Alice EpitropoulosColumbus$531K
- Amy MillerDayton$526K
- Sunil SrivastavaCleveland$508K
- William WileyCleveland$479K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.